An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Through the generous support of Regeneron, four times a year River Journal publishes the on-site report of a high school ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

TTAM Research Institute acquires 23andMe in a $305 million bankruptcy sale, transitioning the DNA testing giant to a ...

Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.